Company

NanoCarrier Co. Ltd

Headquarters: Kashiwa, Japan

Employees: 27

CEO: Mr. Tetsuhito Matsuyama

JPX: 4571 +3.95%

Market Cap

¥13.44 Billion

JPY as of Jan. 1, 2024

US$95.4 Million

Market Cap History

NanoCarrier Co. Ltd market capitalization over time

Evolution of NanoCarrier Co. Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of NanoCarrier Co. Ltd

Detailed Description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

NanoCarrier Co. Ltd has the following listings and related stock indices.


Stock: JPX: 4571 wb_incandescent

Stock: FSX: 3NQ wb_incandescent

Details

Headquarters:

Chuou 144-15

226-39 Wakashiba

Kashiwa, 277-0871

Japan

Phone: 81 4 7197 7621

Fax: 81 4 7197 7624